Welcome to Scribd, the world's digital library. Read, publish, and share books and documents. See more
Standard view
Full view
of .
Look up keyword or section
Like this

Table Of Contents

1. Executive summary
2.2 Objective of the study
2.3 Defining the biopharmaceutical industry
2.3.1 From biotechnology sector to the biopharmaceutical sector
2.3.2 Defining business activities
3. The framework and methodology
3.1 The overall conceptual framework
3.2 Methodological approach
3.2.1 Establishing the inventory of biopharmaceutical enterprises for the survey
3.2.2 Implementation of the survey
3.2.3 Representativeness of the interviewed enterprises
3.2.4 Selection of case studies
4. The biopharmaceutical sector
4.1 Development of biopharmaceutical products
4.2 The biopharmaceutical sector – key figures
4.3 Business dynamics within the biotechnology sector
4.4 R&D cost for developing drug candidates
5. The capital base available for the biopharmaceutical sector
5.1 Different forms of capital
5.1.1 Different sources of capital
5.1.2 Venture capital investment strategies
5.2 Capital supply in Europe
5.3 Comparing the capital supply for life sciences in the US and Europe
5.3.1 Financing gaps in biopharmaceutical product development
5.3.2 Challenges facing the European venture capital industry
5.4 Impact of the financial crisis
6. Strategies for product development
6.1 The pipeline of the biopharmaceutical sector
6.1.1 Number of drug candidates in the pipeline
6.1.2 Grouping the biopharmaceutical enterprises
6.2 Strategies for bringing the drug candidates to the market
7. Financing strategies
7.1 Capital raised for drug development
7.2 Access to capital
7.3 Need for capital
7.5 Impact of capital shortage
7.5.1 External barriers
7.5.2 Internal barriers
7.6 Exit strategies of investors
8. Policy and regulation
8.1 Regulatory environment
8.1.1 Public policy and regulation related to funding
8.1.2 Regulatory measures related to product development and commercialisation
8.2 International markets – barriers, distortions and negotiations
9. Strategic outlook– conclusion and recommendations
9.6 Conclusion and recommendations
9.6.1 Recommendations addressing early stage drug development
Annex 1: List of interviewed expert
Annex 2: Case studies
Symphogen A/S, Denmark
BioArctic Neuroscience AB, Sweden
Apogenix, Germany
MolMed, Italy
Innate Pharma, France
Oryzon Genomics, Spain
Arpida, Switzerland
Cellzome, United Kingdom
0 of .
Results for:
No results containing your search query
P. 1
Financing Biopharma Product Dev En

Financing Biopharma Product Dev En

Ratings: (0)|Views: 75|Likes:
Published by kayeskowsik

More info:

Published by: kayeskowsik on Nov 10, 2011
Copyright:Attribution Non-commercial


Read on Scribd mobile: iPhone, iPad and Android.
download as PDF, TXT or read online from Scribd
See more
See less





You're Reading a Free Preview
Pages 4 to 57 are not shown in this preview.
You're Reading a Free Preview
Pages 59 to 140 are not shown in this preview.

Activity (3)

You've already reviewed this. Edit your review.
1 thousand reads
1 hundred reads
klavdaki3823 liked this

You're Reading a Free Preview

/*********** DO NOT ALTER ANYTHING BELOW THIS LINE ! ************/ var s_code=s.t();if(s_code)document.write(s_code)//-->